Rafael Antonio Freire Carvalho

Prof. Rafael Antonio Freire Carvalho

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2026 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MMMICHELLINE TENORIO ALBUQUERQUE MADRUGA MESQUITA
MICHELLINE TENORIO ALBUQUERQUE MADRUGA MESQUITA
ACAnne Caroline Silva Nogueira da Cruz
Anne Caroline Silva Nogueira da Cruz
RLRafael Abreu Lima
Rafael Abreu Lima
JTJoana Tenório‐Meireles
Joana Tenório‐Meireles
AFArney José Nogueira Farias
Arney José Nogueira Farias
JGJoão Batista Garcia
João Batista Garcia
Background: Repositioning offers a cost‐effective approach to discovering new therapeutic applications for existing medications. Ambroxol, primarily used as a mucolytic for respiratory diseases, has demonstrated anti‐inflammatory, analgesic, and antioxidant properties, suggesting potential benefits in non‐pulmonary conditions. This study conducted a systematic review to evaluate the efficacy of ambroxol in experimental disease models unrelated to the respiratory system. Methods: Following registration in the Open Science Framework and adherence to the PICO strategy for formulating the guiding question, searches were performed in PUBMED/MEDLINE, EMBASE, and SCOPUS using the keywords: (Ambroxol) AND (Anti‐Inflammatory Agents OR Analgesics OR Antioxidants) AND (Animals OR in vivo). The SYRCLE tool assessed methodological quality. Among 353 identified records, eight articles met eligibility criteria. Results: These studies investigated ambroxol's effects in models of gastric lesions, neuropathic pain, psoriasis‐like skin inflammation, hemorrhagic cystitis, and ischemia/reperfusion injuries in the liver and kidneys. Ambroxol doses ranged from 5 to 1000 mg/kg, predominantly administered orally. Its antioxidant properties were demonstrated by reducing free radicals and increasing enzymatic activity (SOD, CAT, GSH). Anti‐inflammatory effects included a decrease in pro‐inflammatory cytokines (TNF‐α, IL‐1β) and histological improvements. Antinociceptive action was observed through inhibition of voltage‐gated sodium channels and reduction of oxidative stress, alleviating neuropathic pain. Conclusions: Despite ambroxol's widespread clinical use, limited research has explored its non‐respiratory applications. Existing studies suggest its promising therapeutic potential, reinforcing the need for further investigation into its role as an alternative treatment for various inflammatory and oxidative stress–related conditions beyond pulmonary diseases.

27 April 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MMMICHELLINE TENORIO ALBUQUERQUE MADRUGA MESQUITA
MICHELLINE TENORIO ALBUQUERQUE MADRUGA MESQUITA
ACAnne Caroline Silva Nogueira da Cruz
Anne Caroline Silva Nogueira da Cruz
JTJoana Tenório Albuquerque Madruga Mesquita Meireles Teixeira
Joana Tenório Albuquerque Madruga Mesquita Meireles Teixeira
ARAmanda Forwille Tissore Forwille Reis
Amanda Forwille Tissore Forwille Reis
GFGustavo Medeiros Frota
Gustavo Medeiros Frota
JGJoão Batista Garcia
João Batista Garcia
Background/Objectives: Ambroxol is a mucolytic agent widely used in the treatment of respiratory diseases; however, evidence in the literature indicates anti-inflammatory, analgesic, and immunomodulatory properties, suggesting potential for therapeutic repositioning. This study aimed to evaluate the analgesic and anti-inflammatory effects of ambroxol in an experimental model of osteoarthritis (OA). Methods: Adult male Wistar rats underwent OA induction on day zero (D0) by sodium monoiodoacetate (MIA) injection and were allocated into the following groups: Healthy, negative control (CTRL−), and groups treated with meloxicam (2 mg/kg) or ambroxol (10, 50, and 100 mg/kg). Treatments were administered orally (gavage) once daily for 28 days. Behavioral tests were performed, including rotarod, walkway gait analysis, weight-bearing, Von Frey, and Rat Grimace Scale assessments, along with radiographic and histopathological analyses and quantification of pro- and anti-inflammatory cytokines (IL-1β, IL-6, and IL-10). Results: Ambroxol treatment improved nociceptive parameters and motor function, reduced radiographic and histopathological scores, and showed performance comparable to meloxicam in several tests. There was a marked reduction in IL-1β and IL-6 levels, while IL-10 levels were lower in ambroxol-treated groups, suggesting early control of the inflammatory response. Conclusions: The results indicate that ambroxol exhibits antinociceptive and anti-inflammatory actions and suggest a potential chondroprotective effect, reinforcing its viability as a candidate for therapeutic repositioning in osteoarthritis. Further studies are required to more precisely elucidate its mechanisms of action, define optimal dosing and treatment duration, and support translation to clinical models.

18 April 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GFGustavo Medeiros Frota
Gustavo Medeiros Frota
WSWilwana Guimarães Barbalho Santos
Wilwana Guimarães Barbalho Santos
JTJoana Tenório-Meireles
Joana Tenório-Meireles
ESEDUARDO RODRIGUES Rodrigues SILVA
EDUARDO RODRIGUES Rodrigues SILVA
ARAmanda Forwille Tissore Forwille Reis
Amanda Forwille Tissore Forwille Reis
MCMaria do Socorro de Sousa Cartágenes
Maria do Socorro de Sousa Cartágenes
Background/Objective: This study evaluated the analgesic and anti-inflammatory effects of ambroxol in an experimental model of endometriosis. Methods: Ambroxol was administered at doses of 10, 50, and 100 mg/kg (Abx 10, Abx 50, and Abx 100) by daily gavage for 21 days. A medroxyprogesterone-treated group (Progesterone) was included as a positive control. Pain was assessed using validated behavioral tests, including the Rat Grimace Scale (RGS), the von Frey test, and the rotarod test. Additionally, interleukin-1β (IL-1β) levels and total leukocyte counts were measured in peritoneal lavage fluid. The volumetric reduction in endometriotic implants was evaluated by ultrasonography, while histopathological analysis characterized inflammatory infiltrate and epithelial layer integrity using a standardized scoring system. Results: All ambroxol doses reduced spontaneous pain manifestations throughout the treatment. The mechanical withdrawal threshold significantly increased from the second week onward, and motor quality improved over the course of the study. A significant reduction in IL-1β levels compared with the negative control (Control(−)) was observed on day 21. Abx 50 and Abx 100 significantly reduced implant volumes (48.2% and 56.2%, respectively) and promoted marked disruption of the endometriotic epithelial layer. When compared with Progesterone, higher doses—particularly 100 mg/kg—demonstrated comparable efficacy. Conclusions: Taken together, these pleiotropic effects support the potential for drug repurposing in endometriosis.

1 April 2025 in Caderno Pedagógico
Verified
Journal Article
Open access
PDF file
TPTereza Cristina Monteiro de Melo Prazeres
Tereza Cristina Monteiro de Melo Prazeres
ALAlice Marques Moreira Lima
Alice Marques Moreira Lima
MMMICHELLINE TENORIO ALBUQUERQUE MADRUGA MESQUITA
MICHELLINE TENORIO ALBUQUERQUE MADRUGA MESQUITA
RCRafael Antonio Freire Carvalho
Rafael Antonio Freire Carvalho
TCTaciana Gabrielle Pinheiro de Moura Carvalho
Taciana Gabrielle Pinheiro de Moura Carvalho
MCMaria do Socorro de Sousa Cartágenes
Maria do Socorro de Sousa Cartágenes
A cistite intersticial/síndrome da bexiga dolorosa (CI/SBD) é uma condição crônica de etiologia desconhecida, caracterizada por dor pélvica e sintomas urinários irritativos. O diagnóstico é desafiador, geralmente realizado por exclusão de outras condições utilização de exames invasivos. Nesse contexto, os microRNAs (miRNAs) surgem como potenciais biomarcadores diagnósticos e alvos terapêuticos promissores. A revisão utilizou bases de dados científicas (PubMed, Web of Science, Scopus e SciELO) para identificar estudos publicados entre 2014 e 2024. Foram selecionados 12 artigos que analisaram a expressão de miRNAs na CI/SBD em modelos experimentais e em amostras de pacientes. Os estudos revisados apontam diversos miRNAs como potenciais biomarcadores e alvos terapêuticos para CI/SBD. A desregulação da expressão de miRNAs está associada à inflamação crônica, remodelação vesical e dor neuropática na CI/SBD. MiR-132, miR-495 e miR-34c foram associados à modulação de vias inflamatórias, enquanto miR-205 demonstrou impacto na integridade do epitélio urotelial. Além disso, exossomos enriquecidos com miR-9 apontaram potencial terapêutico na redução da intensidade da dor. Os artigos obtidos como resultados destacam o papel crítico dos miRNAs na fisiopatologia do CI/SBD, revelando sua aplicabilidade como biomarcadores e alvos terapêuticos inovadores. Estudos futuros são necessários para validar esses marcadores e viabilizar sua implementação clínica, melhorando o diagnóstico precoce e o manejo da doença.